2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE2
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
- Status
- COMPLETED
- Phase
- PHASE2
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
- Status
- UNKNOWN
- Phase
- PHASE1
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Daratumumab in Treating Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
- Status
- COMPLETED
- Phase
- PHASE2
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
- Status
- COMPLETED
- Phase
- PHASE1
Daratumumab for the Treatment of Patients With AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3